Existing vaccines may be less effective against omecron: Moderna CEO

 

Existing vaccines may be less effective against omecron: Moderna CEO

Image source : Such tv

The Code 19 vaccine developed by Moderna is considered one of the most effective vaccines against this disease.

But the CEO of the US company expressed concern that existing vaccines could be less effective against the new strain of the corona virus, Omekron, than Delta.

Stephen Bensell, CEO of Moderna, said that while data on the efficacy of existing vaccines against the new Corona strain may be available for up to 2 weeks, updating existing vaccines to compete with Omicron could take several months.

"I don't think the vaccines are as effective as they were against the Delta," he told the Financial Times.

He noted that pharmaceutical companies might have a difficult time targeting Omecron and older variants, and cautioned that it would be dangerous to limit all of Moderna's production capacity to Omecron vaccines alone.

He said that during this time, stronger booster doses can be given to the aging or weakened immune system.

Pfizer and its German partner BioNtech said on November 26 that they could develop an updated version of their Omicron vaccine within 100 years, but that would only happen if the new Corona strain outperforms the existing vaccine. It has been shown to be resistant to the resulting resistance.

Moderna's chief executive said there have been numerous mutations in the spike protein in the omecron, the part the virus uses to infect human cells.

He added that the rapid spread of the new strain in South Africa indicates that existing omepron vaccines are not very effective, in fact predicting a decrease in the effectiveness of the vaccine.

Following the statement from Moderna's CEO, share prices have fallen further around the world.

Moht Kumar, chief executive of Jefferies, a US multinational investment firm, said Stephen Bensell's statement was cause for concern.

He claimed that his confession was obtained through torture and that his confession was obtained through torture.

He said things will clear up in the coming weeks, but equity markets could face a slowdown at that point.

Other companies that develop cod vaccines are also believed to be considering a response against Omicron.

Pfizer and BioNTech have announced that they will know in two weeks if it is necessary to update the vaccine against this new strain.

The company said that Pfizer and BioNTech could update the mRNA vaccine in six weeks and bring the initial dose to market in 100 days.

However, this will only happen when omecron is shown to be a type of vaccine that avoids the effects of existing vaccines.

The Chinese company Sinuwek also said it was confident of developing a new version of the vaccine on a large scale if necessary, but that would only happen after regulatory approval is obtained and there are concerns. Vaccines need to be updated.

The company added that the technology and production would be similar to the original virus, while the isolation of this new strain could lead to the immediate development of a vaccine, the production of which would not be a problem.

AstraZeneca also said it has started research in Botswana and eSwatini to examine the effects of this new type of vaccine.

The efficacy of the cod vaccine developed by Johnson & Johnson against Omicron is currently being tested and, if necessary, specific vaccines could be developed for this new strain.

Source: suchtv